2 Stocks Climbing After Releasing Earnings

Gilead Sciences Inc. (NASDAQ:GILD) reported its results for the fourth quarter. Net income for Gilead Sciences Inc. rose to $665.1 million (87 cents per share) vs. $629.4 million (76 cents per share) in the same quarter a year earlier. This marks a rise of 5.7% from the year earlier quarter. Revenue rose 10.1% to $2.2 billion from the year earlier quarter. Gilead Sciences Inc. reported adjusted net income of 97 cents per share. By that measure, the company fell short of mean estimate of $1 per share. Analysts were expecting revenue of $2.18 billion.

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Johnson &Johnson (NYSE:JNJ), Bristol Myers Squibb Co. (NYSE:BMY), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Trimeris, Inc. (NASDAQ:TRMS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Hemispherx BioPharma, Inc (AMEX:HEB).

PerkinElmer Inc. (NYSE:PKI) reported its results for the fourth quarter. Reported a loss of $84.6 million (75 cents per diluted share) in the quarter. The medical instruments and supplies company had net income of $292.9 million or $2.49 per share in the year earlier quarter. Revenue rose 14.9% to $540.2 million from the year earlier quarter. PerkinElmer Inc. reported adjusted net income of 62 cents per share. By that measure, the company beat the mean estimate of 51 cents per share. Analysts were expecting revenue of $537.1 million.

“The closing of the Caliper acquisition caps an exceptional year of strategic acquisitions for PerkinElmer,” said Robert Friel, chairman and chief executive officer of PerkinElmer. “We have created a highly differentiated portfolio by significantly strengthening our capabilities in molecular analysis, imaging, sample preparation and informatics, providing our customers with an extensive range of broad-based, application-driven solutions.”

Competitors to Watch: Thermo Fisher Scientific Inc. (NYSE:TMO), Waters Corporation (NYSE:WAT), Beckman Coulter, Inc. (NYSE:BEC), Bruker Corporation (NASDAQ:BRKR), Harvard Bioscience, Inc. (NASDAQ:HBIO), Agilent Technologies Inc. (NYSE:A), Caliper Life Sciences Inc. (NASDAQ:CALP), Becton, Dickinson and Co. (NYSE:BDX), Bio-Rad Laboratories, Inc. (NYSE:BIO), and Sequenom, Inc. (NASDAQ:SQNM).